By continuing to use the site you agree to our Privacy & Cookies policy

NICE set to block use of 'unaffordable' new breast cancer drug

A new breast cancer drug that can extend women’s lives by almost six months will not be recommended for routine NHS use, under draft guidance issued by the National Institute for Health and Care Excellence.

REGISTER FREE
TO CONTINUE READING

  • Access to limited news stories
  • Customised email alerts straight to your inbox (over 30 to choose from)

SUBSCRIBE
(for full online access)

  • Unlimited online access
  • Customised email alerts
  • Weekly delivery of NT magazine
  • 4,500 practice articles in our archive
  • £500+ worth of CPD learning units
  • Only 22p per day
Already registered?
To check that you are registered please enter your email address below

Our records show you are already a registered user. Please sign-in with your password.

By continuing to use the site you agree to our Privacy & Cookies policy

newsletterpromo